GSK plans to market the antibiotic hepotidacin for the treatment of urinary tract infections unresponsive to current antibiotics. Reported by the Daily Mail.
Hepotidacin, which has been in development for over a decade, if approved, will become the first-class antibiotic produced in almost 40 years.
Symptoms of urinary tract infections include a burning pain when you go to the toilet more often than usual and feeling the need to go to the toilet when your bladder is empty. In elderly patients, the infection can cause a dementia-like condition called delirium. There is also the risk of sepsis, which causes about 50,000 deaths per year. Most often, infections develop in women, and modern antibiotics are often ineffective due to bacterial resistance to them.
Hepotidasine is expected to be used to treat a number of other diseases, including gonorrhea, which is considered one of the most treatment-resistant infections.
GSK, the pharmaceutical company that produces geopotidacin, plans to apply for US approval in the spring of 2023.
Barbara Dickson is a seasoned writer for “Social Bites”. She keeps readers informed on the latest news and trends, providing in-depth coverage and analysis on a variety of topics.